1.
Yagisawa T, Toma H, Tanabe K, Ishikawa N, Tokumoto N, Iguchi Y, Goya N, Nkazwawa H, Takahashi K, Ota K: Long-term outcome of renal transplantation in hepatitis B surface antigen-positive patients in cyclosporin era. Am J Nephrol 1997;17:440–444.
2.
Huang C: Hepatitis in patients with end-stage renal disease. J Gastroenterol Hepatol 1997;12:236–241.
3.
Pereira B, Milford E, Kirkman R, Levey A: Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991;325:454–460.
4.
Pereira B, Levey A: Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997;51:981–999.
5.
Kallinowski B, Theilmann L, Gmelin K, Andrassy K, Deppermann B, Weinel B, Kommerell B: Prevalence of antibodies to hepatitis C virus in hemodialysis patients. Nephron 1991;59:236–238.
6.
Kallinowski B, Theilmann L, Gmelin K, Rambausek M, Möhring M, Kommerell B: Incidence and prevalence of antibodies to hepatitis C virus in kidney transplanted patients (letter). J Hepatol 1991;12:404–405.
7.
Kallinowski B, Seipp S, Fatehi S, Sommerfeld U, Andrassy K, Stremmel W, Theilmann L: Significance of hepatitis B, hepatitis C and GBV-C in ANCA-positive hemodialysis patients. Nephron 1997;77:357–358.
8.
Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel J, Bernard B, Opolon P, Coriat P, Bitker M: Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999;29:257–263.
9.
First M: Hepatitis C virus infection in the renal transplant recipient. Nephrol Dial Transplant 2000;15:60–64.
10.
De Francesco R: Molecular virology of the hepatitis C virus. J Hepatol 1999;31(suppl 1):47–53.
11.
Mondelli M, Silini E: Clinical significance of hepatitis C virus genotypes. J Hepatol 1999;31(suppl 1):54–60.
12.
Simmonds P: Viral heterogenicity of hepatitis C virus. J Hepatol 1999;31(suppl 1):54–60.
13.
Hasselborn H, Hofmann F: Übertragung von HBV, HCV und HIV durch infektiöses medizinisches Personal. Eine Übersichtsdarstellung. Chirurg 2000;71:389–395.
14.
Esteban J, Esteban R, Viladomiu L: Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989;ii:294–297.
15.
Donahue J, Munoz A, Ness P, Brown D, Yawn H, Mcallister H, Reizt B, Nelson K: The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327:369–373.
16.
Chan T, Lok A, Cheng I, Chan R: Prevalence of hepatitis C virus infection in hemodialysis patients: A longitudinal study comparing the results of RNA and antibody assay. Hepatology 1993;17:5–8.
17.
Pereira B: Hepatitis C in organ transplantation: Its significance and influence on transplantation policies. Curr Opin Nephrol Hypertens1993;2:912–922.
18.
Goodnough L, Becker M, Kauter M, Aubuchon J: Transfusion medicine. N Engl J Med 1999;340:438–447.
19.
Bukh J, Wantzin P, Krogsgaard K, Knudsen F, Purcell R, Miller R: High prevalence of hepatitis C virus (HCV) in dialysis patients: Failure of commercially available antibody tests to identify a significant number of patients with HCV infection. J Infect Dis 1993;168:1343–1348.
20.
Daichou Y, Kurashige S, Hashimotos S, Suzuki S: Characteristic cytokine products of Th1 and Th2 cells in haemodialysis patients. Nephron 1999;83:237–245.
21.
Kallinowski B, Ahmadi R, Seipp S, Bommer J, Stremmel W: Clinical impact of GB-C virus in haemodialysis patients. Nephrol Dial Transplant 1998;13:93–98.
22.
Knudsen F, Wantzin P, Rasmussen Ladefoged S, Lokkegaard N, Rasmussen L, Lassen A, Krogsgaard K: Hepatitis C in dialysis patients: Relationship to blood transfusions, dialysis and liver disease. Kidney Int 1993;43:1353–1356.
23.
Glicklich D, Thung S, Kapoian T, Tellis V, Reinus J: Comparison of clinical features and liver histology in hepatitis C-positive dialysis patients and renal transplant patients. Am J Gastroenterol 1999;94:159–163.
24.
Caramelo C, Bartolome J, Albalate M: Undiagnosed hepatitis C virus infection in hemodialysis patients: Value of HCV RNA and liver enzyme levels. Kidney Int 1996;50:2027–2031.
25.
Guh J , Lai Y, Yang C, Yang C, Chen S, Chuang W, Hsu T, Chen H, Chan W, Tsai J: Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995;69:459–465.
26.
Rao K, Anderson R, Dasiske B, Dahe R: Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients. Am J Med 1993;94:241–250.
27.
Pol S, Romeo R, Zins B, Driss F, Lebkin B, Carnot F, Berthelot P, Brechot C: Hepatitis C virus RNA in anti-HCV positive hemodialysed patients. Kidney Int 1993;44:1097–1100.
28.
Barril G: Hepatitis C virus-induced liver disease in dialysis patients. Nephrol Dial Transplant 2000;15(suppl 8):42–45.
29.
Manns M, Mchutchinson J, Gordons M, Rustgi V, Shiffmann M, Reindollar R, Goodman Z, Koury K, Ling M, Albrecht J and the International Hepatitis Interventional Therapy Group: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958–964.
30.
Fabrizi F, Locatelli F: Combination of interferon alpha and ribavirin in the treatment of hepatitis C: Implications for the clinical nephrologist. Nephrol Dial Transplant 1999;14:2079–2081.
31.
Pol S, Thiers V, Carnot F, Zins B, Romeo R, Berthelot P, Brechot C: Efficacy and tolerance of alpha 2b interferon therapy on HCV-infection of hemodialyzed patients. Kidney Int 1995;47:1412–1418.
32.
Campistol J, Esforzado N, Martinez J, Rosello L, Veciana L, Modpons M, Piera J, Oliva J, Costa J, Barrera J: Efficacy and tolerance of interferon-alpha 2b in the treatment of chronic hepatitis C infection in hemodialysis patients: Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999;14:2704–2709.
33.
Casanovas T, Baliellas C, Benasco C, Serrano T, Casano G, Gonzalez M, Andres E, Vernet S, Casais L: Efficacy of interferon for chronic hepatitis C virus related hepatitis in kidney transplant candidates on hemodialysis. Am J Gastroenterol 2001;96:1170–1177.
34.
Degos F, Pol S, Chaix M, Laffitte V, Buffet C, Bernard P, Degott R, Chevret S: The tolerance and efficacy of interferon-alfa in haemodialysis patients with HCV infection: A multicentre prospective study. Nehprol Dial Transplant 2001;16:1017–1023.
35.
Morales J, Campistol J: Transplantation in the patient with hepatitis C. J Am Soc Nephrol 2000;11:1343–1353.
36.
Martin P, Mitra S, Farrington K, Martin N, Modi M: Pegylated (40 kDA) interferon alfa-2a is unaffected by renal impairment. Hepatolgoy 2000;32:442A.
37.
Roth D, Zucker K, Cirocco R, Demattos A, Burke G, Nery J, Esquenzai V, Babischkin S, Miller J: The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 1994;45:238–244.
38.
Legendre C, Garrigue V, Le Bihan C, Mamzer Bruneel M, Chaix M, Landais P, Kreis H, Pol S: Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998;65:667–670.
39.
Pereira B, Natov S, Bouthot B, Murthy B, Ruthazer R, Schmid C, Levey A and the New England Bank Hepatitis C Study group: Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int 1998;53:1374–1381.
40.
Pol S, Cavalcanti R, Carnot F, Legendre C, Driss F, Chaix M, Thervet E, Chkoff N, Brechot C, Berthelot P, Kreis H: Azathioprine hepatitis in kidney transplant recipients: A predisposing role of chronic viral hepatitis. Transplantation 1996;61:1774–1776.
41.
Munoz de Bustillo E, Benito A, Colina F, Andres A, Dominguez G, Munoz M, Rodicio J, Morales J: Fibrosing cholestatic hepatitis in hepatitis C virus-infected transplant recipients. J Am Soc Nephrol 1998;9:109–113.
42.
Toth C, Pascual M, Chung R, Graeme-Cook F, Dienstag J, Brian A, Cosimi A: Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation. Transplantation 1998;66:1254–1258.
43.
Hanafasu T, Ichikawa Y, Kishikawa H, Kyo M, Fukunishi T, Kokado Y, Okuyama A, Shinji Y, Nagano S: Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998;66:471–476.
44.
Vosnides C: Hepatits C in renal transplantation (nephrology forum). Kidney Int 1997;52:843–861.
45.
D’Amico G, Fornasieri A: Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus. Am J Kidney Dis 1995;25:361–369.
46.
Cruzado J, Gil-Vernet S, Ercilla G, Seron D, Carrera M, Bas J, Torras J, Alsina J, Grinyo J: Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts. J Am Soc Nephrol 1996;7:2469–2475.
47.
Brunkhorst R, Kliem V, Koch K: Recurrence of membranoproliferative glomerulonephritis after renal transplantation in a patient with chronic hepatitis C. Nephron 1996;72:456–467.
48.
Morales J, Campistol J, Andres A, Rodicio J: Glomerular disease in patients with hepatitis C virus infection after renal transplantation. Curr Opin Nephrol Hypertens 1997;6:511–515.
49.
Morales J, Pascual M, Campistol J, Fernandez-Zalvan G, Munos G, Andre A, Praga M, Martinez M, Usera G, Fuertes A, Oppenheimer F, Artas P, Darnell A, Rodicio J: Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 1997;63:1634–1639.
50.
Baid S, Pascual M, Williams W, Tolkoff-Rubin N, Johnson S, Collins B, Chung R, Delmonico F, Cosimi A, Colvin R: Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. Am J Kidney Dis 1999;33:1040–1048.
51.
Port F, Wolfe R, Mauger E, Berling D, Jiang K: Comparison of survival probabilities for dialysis patients versus cadaveric renal transplant recipients. JAMA 1993;270:1339–1343.
52.
Rostaing L: Treatment of hepatitis C virus infection after renal transplantation. New insights. Nephrol Dial Transplant 2000;15(suppl 8):74–76.
53.
Magnone M, Holley J, Shapiro R, Scantlebury V, McCauley J, Jordan M, Starzl T, Johnson J: Interferon-α-induced acute renal allograft rejection. Transplantation 1995;59:1068–1070.
54.
Smith JP: Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 1997;42:1681–1687.
55.
Garnier J, Chevalier P, Dubernard J: Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transplant Proc 1997;29:783.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.